CSTL
Castle Biosciences Inc

1,004
Mkt Cap
$710.99M
Volume
198,915.00
52W High
$35.84
52W Low
$14.59
PE Ratio
-68.91
CSTL Fundamentals
Price
$24.51
Prev Close
$24.18
Open
$24.39
50D MA
$22.65
Beta
1.24
Avg. Volume
374,987.76
EPS (Annual)
$0.6236
P/B
1.56
Rev/Employee
$436,358.74
Loading...
Loading...
News
all
press releases
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
Zacks·2d ago
News Placeholder
More News
News Placeholder
How Much Upside is Left in Castle Biosciences (CSTL)? Wall Street Analysts Think 50.08%
The consensus price target hints at a 50.1% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2d ago
News Placeholder
What Makes Castle Biosciences (CSTL) a New Strong Buy Stock
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4d ago
News Placeholder
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +129.41% and +16.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
New Strong Sell Stocks for August 1st
CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.
Zacks·3mo ago
News Placeholder
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company...
Business Wire·8mo ago
News Placeholder
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile...
Business Wire·9mo ago
News Placeholder
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter...
Business Wire·9mo ago

Latest CSTL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.